Etentamig Reduced Multiple Myeloma Progression Risk
In a Phase 3 trial, patients with relapsed or refractory multiple myeloma saw improved outcomes with a new treatment.
Updated on Sept. 26, 2026 in Cancer
The Phase 3 CERVINO trial found that etentamig significantly outperformed standard therapies in patients with heavily pretreated multiple myeloma. For those managing this complex condition, the study suggests a potential new path for care following prior treatment failures.
Why it matters
This development offers a potential new option for patients who have exhausted multiple lines of standard therapy, including proteasome inhibitors and immunomodulatory drugs. It represents a significant step toward improving outcomes in refractory cases where treatment options are currently limited.
In a Phase 3 randomized trial of 393 patients, etentamig achieved a 74.0% overall response rate compared to 45.7% for standard therapy. While this suggests higher efficacy, researchers noted significant side effects, including a 28.3% rate of cytokine release syndrome and a 27.7% grade 3/4 infection rate.
The players
Atrium Health Levine Cancer Institute
A research center specializing in advanced oncology care and the investigation of new hematologic malignancy treatments.
Wake Forest University
A research institution contributing clinical expertise to the evaluation of emerging therapies for relapsed cancers.
The details
Etentamig utilizes a single step-up dosing mechanism to target relapsed or refractory disease in patients who have been triple-class exposed to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. By modulating immune response, the treatment reduced the risk of disease progression or death by 60 percent. Researchers observed that while highly effective, the therapy requires careful monitoring for immune-related complications like cytokine release syndrome and infections.
Timeline
September 2026: Data from the CERVINO trial was presented at the IMS meeting.
Health Landscape
The CERVINO trial establishes a new benchmark for evaluating efficacy in heavily pretreated multiple myeloma patients compared to historical standards of care. This study marks a potential shift in the clinical approach for triple-class-exposed patients by demonstrating superior response rates.
Patients dealing with relapsed or refractory multiple myeloma should discuss these findings with their oncologist to understand if such therapies are appropriate for their specific disease profile. Because of the risk of serious side effects like infections and immune responses, careful monitoring is a critical component of this treatment.
The takeaway
Etentamig demonstrated a 60 percent reduction in disease progression risk, providing a promising outlook for complex, relapsed cases. Patients should work closely with their hematology-oncology team to monitor for immune-related symptoms during any new treatment protocol.
What happens next
A phase 3 trial is scheduled to launch to evaluate etentamig in combination with pomalidomide for patients in early relapse, alongside an ongoing phase 2/3 study for newly diagnosed patients.
Further reading
For more information on the latest approaches to managing blood-based malignancies, visit Cancer.
